Abstract 1654: Pre-clinical activity of the Wnt/Beta-catenin pathway inhibitor RXC004 in models of biliary tract cancer
Simon A. Woodcock(Bio-Medical Science (South Korea)), Caroline Phillips(Redx Pharma (United Kingdom)), Lucy Frost(Medicines Discovery Catapult), Catherine Eagle, Richard Armer(Redx Pharma (United Kingdom)), Inder Bhamra(Redx Pharma (United Kingdom)), Gayle Marshall(Medicines Discovery Catapult), Dorottya Keppel(4D Pharma (United Kingdom)), Kevin J. Randall(Medicines Discovery Catapult), Jane Robertson(Cancer Research UK), Eleanor Platt(Medicines Discovery Catapult)
Cited by 0
Related Papers
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
|British Journal of Cancer|2018|233